Nasdaq · CIK 0001139685
AIDX 20/20 Biolabs, Inc.
Insider trading from SEC Form 4. Last filing Apr 6, 2026.
20/20 Biolabs, Inc. (AIDX) has 7 SEC Form 4 filings on file from 7 insiders, the latest filed on Apr 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at 20/20 Biolabs, Inc., scored.
Transactions
Every row filed, 13 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Jiming Zhou Chief Operating Officer | AGrant or award Stock Optionderivative | +150,000 | $0.00 | $0 | 150,000 | Apr 6, 2026 |
| Apr 2, 2026 | Alan B. Bergman Chief Financial Officer | AGrant or award Stock Optionderivative | +100,000 | $0.00 | $0 | 100,000 | Apr 6, 2026 |
| Mar 3, 2026 | Jonathan M Cohen Chief Executive Officer | AGrant or award Stock Optionderivative | +352,936 | $0.00 | $0 | 352,936 | Mar 4, 2026 |
| Feb 19, 2026 | Richard M Cohen director | CConversion Common Stock | +7,700 | $0.00 | $0 | 7,700 | Feb 23, 2026 |
| Feb 19, 2026 | John G. Compton director | CConversion Common Stock | +7,669 | $0.00 | $0 | 14,335 | Feb 23, 2026 |
| Feb 19, 2026 | Michael A. Ross director | CConversion Common Stock | +31 | $0.00 | $0 | 31 | Feb 23, 2026 |
| Feb 19, 2026 | John Woodson Rollins director | CConversion Common Stock | +13,029 | $0.00 | $0 | 24,140 | Feb 23, 2026 |
| Feb 19, 2026 | Richard M Cohen director | CConversion Series A-2 Preferred Stockderivative | -7,700 | - | - | 0 | Feb 23, 2026 |
| Feb 19, 2026 | John G. Compton director | CConversion Series A-2 Preferred Stockderivative | -7,669 | - | - | 0 | Feb 23, 2026 |
| Feb 19, 2026 | Michael A. Ross director | CConversion Series A-2 Preferred Stockderivative | -31 | - | - | 0 | Feb 23, 2026 |
| Feb 19, 2026 | John Woodson Rollins director | CConversion Common Stock | +6,135 | $0.00 | $0 | 30,275 | Feb 23, 2026 |
| Feb 19, 2026 | John Woodson Rollins director | CConversion Series A Preferred Stockderivative | -13,029 | - | - | 0 | Feb 23, 2026 |
| Feb 19, 2026 | John Woodson Rollins director | CConversion Series A-2 Preferred Stockderivative | -6,135 | - | - | 0 | Feb 23, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Alan B. BergmanChief Financial Officer
- Richard M Cohendirector
- Jonathan M CohenChief Executive Officer
- John G. Comptondirector
- John Woodson Rollinsdirector
- Michael A. Rossdirector
- Jiming ZhouChief Operating Officer
Questions about AIDX
Answered from the filings on this page, as of the latest one.
Are insiders buying AIDX?
No. In the last 90 days no insider at 20/20 Biolabs, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AIDX on the open market?
No open-market trade has been scored at 20/20 Biolabs, Inc.. The latest Form 4 on file was filed on Apr 6, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at 20/20 Biolabs, Inc.?
7 people have filed a Form 4 at 20/20 Biolabs, Inc., among them Alan B. Bergman (Chief Financial Officer), Richard M Cohen (director), Jonathan M Cohen (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.